Lectenz® Bio receives NIH SBIR Phase I

Lectenz® Bio receives NIH SBIR Phase I

The National Institute of General Medical Sciences (NIGMS) awards Lectenz® Bio a second SBIR Phase I to apply the GlycoSenseTM technology to monitoring glycoenzyme engineering reactions.